These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 20602821)
1. Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy. Oliveira IS; Pontes-Junior J; Abe DK; Crippa A; Dall'oglio MF; Nesralah AJ; Leite KR; Reis ST; Srougi M Int Braz J Urol; 2010; 36(3):292-9. PubMed ID: 20602821 [TBL] [Abstract][Full Text] [Related]
2. Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS). Lellig E; Gratzke C; Kretschmer A; Stief C World J Urol; 2015 Jul; 33(7):917-22. PubMed ID: 26047652 [TBL] [Abstract][Full Text] [Related]
3. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL; J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734 [TBL] [Abstract][Full Text] [Related]
4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488 [TBL] [Abstract][Full Text] [Related]
5. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
6. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Ravery V; Boccon-Gibod LA; Dauge-Geffroy MC; Billebaud T; Delmas V; Meulemans A; Toublanc M; Boccon-Gibod L Urology; 1994 Sep; 44(3):371-6. PubMed ID: 7521093 [TBL] [Abstract][Full Text] [Related]
7. Calculated volume of prostate cancer identifies patients with clinical stage T1C disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study. Olumi AF; Richie JP; Schultz DJ; D'Amico AV Urology; 2000 Aug; 56(2):273-7. PubMed ID: 10925093 [TBL] [Abstract][Full Text] [Related]
8. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria. Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782 [TBL] [Abstract][Full Text] [Related]
9. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. Epstein JI; Walsh PC; Carmichael M; Brendler CB JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797 [TBL] [Abstract][Full Text] [Related]
10. Implications of greater short-term PSA recurrence with laparoscopic as compared to retropubic radical prostatectomy for Japanese clinically localized prostate carcinomas. Akita H; Okamura T; Ando R; Nagata D; Naruyama H; Yamada Y; Naiki T; Yasui T; Tozawa K; Kohri K Asian Pac J Cancer Prev; 2011; 12(11):2959-61. PubMed ID: 22393971 [TBL] [Abstract][Full Text] [Related]
11. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203 [TBL] [Abstract][Full Text] [Related]
12. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060 [TBL] [Abstract][Full Text] [Related]
13. Minute focus of prostate cancer on needle biopsy: correlation with radical prostatectomy specimen. Montanari E; Del Nero A; Gazzano G; Mangiarotti B; Bernardini P; Longo F; Cordima G; Itri E Arch Ital Urol Androl; 2009 Mar; 81(1):9-12. PubMed ID: 19499751 [TBL] [Abstract][Full Text] [Related]
14. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients. Caster JM; Falchook AD; Hendrix LH; Chen RC Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621 [TBL] [Abstract][Full Text] [Related]
15. Outcome of radical prostatectomy in patients meeting criteria for active surveillance. Dellavedova T; Ponzano RM; Sarria JP; Minuzzi PG; Nobile RH; Minuzzi FG Arch Esp Urol; 2013 May; 66(4):342-9. PubMed ID: 23676537 [TBL] [Abstract][Full Text] [Related]
16. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Kupelian P; Katcher J; Levin H; Zippe C; Klein E Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737 [TBL] [Abstract][Full Text] [Related]
17. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714 [TBL] [Abstract][Full Text] [Related]
19. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068 [TBL] [Abstract][Full Text] [Related]
20. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors]. Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]